Jan. 9, 2019, San Francisco, CA - On the final day of the largest biotechnology and pharmaceutical partnering week at the Juvenescence Longevity Showcase two leading longevity biotechnology companies, Elevian and Insilico Medicine announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.

Insilico Medicine is an Artificial Intelligence (AI) company developing an end-to-end pipeline for automated target identification, small molecule generation, prediction of clinical trials outcomes and aging research.

The collaboration will take advantage of Insilico's generative adversarial networks (GANs) and reinforcement learning (RL) AI technologies to discover novel small molecules that target the GDF11 pathway, which has been demonstrated to play an important role in aging and age-related disease.

GDF11 is an exciting pathway and Elevian's scientists are world leaders in this field coming from Harvard and other prestigious institutions.

Their management has a solid vision and is committed to doing great research and turn it into the life-saving products in record time," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine

In order to succeed in this endeavor, the companies will utilize state of the art techniques in AI-enabled drug discovery.

The text above is a summary, you can read full article here.